RA Capital

RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

Ryan Berry

Analyst

Michael Calore

Director of Investor Relations

Tess Cameron

Principal

Parker Cassidy

Principal

Amanda Daniels

Operations Team

Derek DiRocco

Partner

Matthew Hammond

Principal

Nathaniel B. Horwitz

Principal

Peter Kolchinsky Ph.D

Managing Partner

Andrew Levin Ph.D

Managing Partner

Daniel Marks Ph.D

Principal

Josh Resnick

Managing Director

Zach Scheiner

Principal

Rajeev Shah

Managing Partner

Jake Simson

Partner

Laura Tadvalkar

Principal

Jack Vailas

Senior Associate

Past deals in Nanotechnology

Nodexus

Series A in 2021
Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Graphite Bio

Series B in 2021
At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.

Wave Life Sciences

Series B in 2015
Wave Life Sciences Ltd. is a clinical stage genetic medicine company that specializes in the design and production of novel stereopure oligonucleotides using its proprietary PRISM platform. Focused on addressing genetic defects, the company develops therapies aimed at reducing the expression of harmful proteins or converting dysfunctional proteins into functional ones. Its primary research areas include neurologic conditions affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The founding scientists, Gregory Verdine and Takeshi Wada, are recognized leaders in the field, contributing their expertise to the development of innovative nucleic acid therapeutics.

Wave Life Sciences

Series A in 2015
Wave Life Sciences Ltd. is a clinical stage genetic medicine company that specializes in the design and production of novel stereopure oligonucleotides using its proprietary PRISM platform. Focused on addressing genetic defects, the company develops therapies aimed at reducing the expression of harmful proteins or converting dysfunctional proteins into functional ones. Its primary research areas include neurologic conditions affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The founding scientists, Gregory Verdine and Takeshi Wada, are recognized leaders in the field, contributing their expertise to the development of innovative nucleic acid therapeutics.

T2 Biosystems

Series D in 2011
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

T2 Biosystems

Series C in 2010
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.